Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/51291
Type
ArticleCopyright
Restricted access
Collections
Metadata
Show full item record21
CITATIONS
21
Total citations
17
Recent citations
3.94
Field Citation Ratio
1.31
Relative Citation Ratio
DOXYCYCLINE REVERSES COGNITIVE IMPAIRMENT, NEUROINFLAMMATION AND OXIDATIVE IMBALANCE INDUCED BY D-AMPHETAMINE MANIA MODEL IN MICE: A PROMISING DRUG REPURPOSING FOR BIPOLAR DISORDER TREATMENT?
Mania
Doxycycline
D-amphetamine
Cognitive impairment
Neuroinflammation
Microglial activation
Oxidative stress
Author
Affilliation
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil / Federal University of Goiás. Faculty of Pharmacy. LabMol - Laboratory for Molecular Modeling and Drug Design. Goiânia, GO, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Federal University of Goiás. Faculty of Pharmacy. LabMol - Laboratory for Molecular Modeling and Drug Design. Goiânia, GO, Brazil.
Federal University of Goiás. Faculty of Pharmacy. LabMol - Laboratory for Molecular Modeling and Drug Design. Goiânia, GO, Brazil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Laboratório de Ultraestrutura. Recife, PE, Brazil / Instituto Nacional de Ciência e Tecnologia de Neuroimunomodulação. Rio de Janeiro, RJ, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil / National Institute for Translational Medicine. Ribeirão Preto, SP, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil.
Federal University of Goiás. Faculty of Pharmacy. LabMol - Laboratory for Molecular Modeling and Drug Design. Goiânia, GO, Brazil.
Federal University of Goiás. Faculty of Pharmacy. LabMol - Laboratory for Molecular Modeling and Drug Design. Goiânia, GO, Brazil.
Fundação Oswaldo Cruz. Instituto Aggeu Magalhães. Laboratório de Ultraestrutura. Recife, PE, Brazil / Instituto Nacional de Ciência e Tecnologia de Neuroimunomodulação. Rio de Janeiro, RJ, Brazil.
Universidade Federal do Ceará. Faculty of Medicine. Department of Physiology and Pharmacology. Neuropharmacology Laboratory, Drug Research and Development Center. Fortaleza, CE, Brazil / National Institute for Translational Medicine. Ribeirão Preto, SP, Brazil.
Abstract
Immune-inflammatory mechanisms are involved in the pathophysiology of bipolar disorder. Tetracyclines present neuroprotective actions based on their anti-inflammatory and microglia suppressant effects. Doxycycline (DOXY) is a tetracycline that demonstrates a better usage profile with protective actions against inflammation and CNS injury. Here, we investigated the effects of DOXY against behavioral, neuroinflammatory, and pro-oxidative changes induced by the d-amphetamine mania model. Adult mice were given d-amphetamine 2.0 mg/kg or saline for 14 days. Between days 8 and 14, received lithium, DOXY (25 or 50 mg/kg), or their combination (lithium+DOXY) on both doses. We collected the brain areas prefrontal cortex (PFC), hippocampus, and amygdala to evaluate inflammatory and oxidative alterations. D-amphetamine induced hyperlocomotion and impairment in recognition and working memory. Lithium reversed hyperlocomotion but could not restore cognitive alterations. DOXY alone (at both doses) or combined with lithium reversed d-amphetamine-induced cognitive changes. DOXY, better than lithium, reversed the d-amphetamine-induced rise in TNFα, MPO, and lipid peroxidation. DOXY reduced the hippocampal expression of Iba1 (a marker of microglial activation), inducible nitric oxide synthase (iNOS), and nitrite. Combined with lithium, DOXY increased the phosphorylated (inactivated) form of GSK3β (Ser9). Therefore, DOXY alone or combined with lithium reversed cognitive impairment and neuroinflammation induced by the mice's d-amphetamine model. This study points to DOXY as a promising adjunctive tool for bipolar disorder treatment focused on cognition and neuroimmune changes. Our data provide the first rationale for clinical trials investigating DOXY therapeutic actions in bipolar disorder mania.
Keywords
Bipolar disorderMania
Doxycycline
D-amphetamine
Cognitive impairment
Neuroinflammation
Microglial activation
Oxidative stress
Share